Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have been given a consensus recommendation of “Moderate Buy” by the eighteen research firms that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $110.00.

Several brokerages recently weighed in on GPCR. The Goldman Sachs Group upgraded Structure Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 20th. Guggenheim upped their price target on Structure Therapeutics from $90.00 to $140.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. BMO Capital Markets set a $145.00 price target on Structure Therapeutics and gave the stock an “outperform” rating in a report on Tuesday, March 17th. HC Wainwright cut their price objective on Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, March 16th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research report on Friday, December 12th.

Structure Therapeutics Stock Performance

Shares of GPCR stock opened at $53.48 on Friday. Structure Therapeutics has a twelve month low of $13.22 and a twelve month high of $94.90. The stock has a market cap of $3.79 billion, a price-to-earnings ratio of -67.70 and a beta of -1.17. The company’s 50-day moving average price is $64.67 and its 200-day moving average price is $52.40.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.14). As a group, equities research analysts predict that Structure Therapeutics will post -0.82 EPS for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Several large investors have recently made changes to their positions in the stock. CWM LLC lifted its stake in Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 125 shares in the last quarter. HighTower Advisors LLC raised its holdings in shares of Structure Therapeutics by 3.6% in the 4th quarter. HighTower Advisors LLC now owns 9,320 shares of the company’s stock valued at $648,000 after buying an additional 320 shares during the period. State of Wyoming raised its holdings in shares of Structure Therapeutics by 29.7% in the 4th quarter. State of Wyoming now owns 1,761 shares of the company’s stock valued at $122,000 after buying an additional 403 shares during the period. PNC Financial Services Group Inc. lifted its stake in Structure Therapeutics by 9.4% during the 3rd quarter. PNC Financial Services Group Inc. now owns 4,828 shares of the company’s stock worth $135,000 after acquiring an additional 413 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Structure Therapeutics by 4.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,888 shares of the company’s stock valued at $757,000 after acquiring an additional 444 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.